Golden Biotechnology Corporation (TPEX:4132)
Taiwan
· Delayed Price · Currency is TWD 23.00
+3.15 (15.87%)
At close: Dec 5, 2025
Golden Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 44.58 | 40.92 | 63.43 | 217.83 | 81.77 | 88.83 | Upgrade
|
| Revenue Growth (YoY) | -22.45% | -35.49% | -70.88% | 166.39% | -7.95% | 6.64% | Upgrade
|
| Cost of Revenue | 55.77 | 47.93 | 47.37 | 66.03 | 69.08 | 64.17 | Upgrade
|
| Gross Profit | -11.19 | -7.01 | 16.06 | 151.79 | 12.69 | 24.66 | Upgrade
|
| Selling, General & Admin | 199.61 | 197.47 | 179.12 | 170.14 | 171.43 | 177.93 | Upgrade
|
| Research & Development | 94.21 | 153.22 | 202.52 | 278.42 | 265.1 | 194.77 | Upgrade
|
| Operating Expenses | 293.82 | 350.69 | 381.64 | 448.56 | 436.53 | 372.59 | Upgrade
|
| Operating Income | -305.01 | -357.7 | -365.58 | -296.77 | -423.85 | -347.94 | Upgrade
|
| Interest Expense | -10.54 | -8.42 | -6.73 | -4.08 | -3.69 | -4.14 | Upgrade
|
| Interest & Investment Income | 1.54 | 2.4 | 8.81 | 4.33 | 0.33 | 0.28 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.34 | 2.75 | 2.52 | 26.56 | -5.82 | -8.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.41 | 0.24 | 0.3 | 0.22 | 1.51 | 0.54 | Upgrade
|
| EBT Excluding Unusual Items | -314.93 | -360.73 | -360.68 | -269.74 | -431.52 | -359.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.23 | - | -9.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.15 | 0.15 | 1.01 | 0.44 | - | -0.48 | Upgrade
|
| Asset Writedown | -0.04 | - | -1.68 | -2.23 | -10.01 | -19.2 | Upgrade
|
| Other Unusual Items | 0 | 0 | - | - | - | -0.49 | Upgrade
|
| Pretax Income | -314.81 | -360.58 | -361.35 | -271.76 | -441.53 | -388.82 | Upgrade
|
| Income Tax Expense | 0.12 | 0.12 | 0.29 | 0.12 | 2.3 | 2.55 | Upgrade
|
| Net Income | -314.93 | -360.7 | -361.64 | -271.88 | -443.84 | -391.38 | Upgrade
|
| Net Income to Common | -314.93 | -360.7 | -361.64 | -271.88 | -443.84 | -391.38 | Upgrade
|
| Shares Outstanding (Basic) | 161 | 151 | 142 | 142 | 132 | 126 | Upgrade
|
| Shares Outstanding (Diluted) | 161 | 151 | 142 | 142 | 132 | 126 | Upgrade
|
| Shares Change (YoY) | 12.93% | 5.90% | - | 7.36% | 5.40% | 9.32% | Upgrade
|
| EPS (Basic) | -1.96 | -2.39 | -2.54 | -1.91 | -3.35 | -3.11 | Upgrade
|
| EPS (Diluted) | -1.96 | -2.39 | -2.54 | -1.91 | -3.35 | -3.11 | Upgrade
|
| Free Cash Flow | -238.99 | -264.04 | -276.2 | -260.3 | -207.31 | -269.02 | Upgrade
|
| Free Cash Flow Per Share | -1.49 | -1.75 | -1.94 | -1.83 | -1.56 | -2.14 | Upgrade
|
| Gross Margin | -25.09% | -17.14% | 25.31% | 69.69% | 15.52% | 27.76% | Upgrade
|
| Operating Margin | -684.15% | -874.18% | -576.36% | -136.24% | -518.35% | -391.71% | Upgrade
|
| Profit Margin | -706.41% | -881.51% | -570.15% | -124.81% | -542.80% | -440.61% | Upgrade
|
| Free Cash Flow Margin | -536.07% | -645.30% | -435.45% | -119.50% | -253.53% | -302.87% | Upgrade
|
| EBITDA | -280.29 | -329.94 | -331.43 | -258.17 | -386.21 | -307.82 | Upgrade
|
| EBITDA Margin | - | - | - | -118.52% | - | - | Upgrade
|
| D&A For EBITDA | 24.72 | 27.76 | 34.15 | 38.6 | 37.64 | 40.11 | Upgrade
|
| EBIT | -305.01 | -357.7 | -365.58 | -296.77 | -423.85 | -347.94 | Upgrade
|
| EBIT Margin | - | - | - | -136.24% | - | - | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.